Cytokine Gene Therapy

Phase I Trial Evaluates IL-2 Gene Transfer in Cancer Patients

Published in Gene Therapy Weekly, January 13th, 2000

A Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 (IL-2) gene in patients with metastatic renal cancer, colorectal cancer and lymphoma shows that the procedure is safe and warrants further investigation.

"Natural killer-like T lymphocytes termed cytokine-induced killer (CIK) cells have been shown to eradicate established tumors in a severe combined immune deficient (SCID) mouse/human lymphoma model," wrote I.G.H. Schmidtwolf and colleagues from Humboldt University, Division Hematological Oncology, Germany. "Recently, we demonstrated that CIK cells transfected with cytokine genes possess an improved...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2000-01-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry